Overview

This Study is an Open-lable, Phase I Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.

Status:
NOT_YET_RECRUITING

Trial end date:
2028-12-10

Target enrollment:

Participant gender:

Summary

This is a First-in-Human, open-label, phase I dose-escalation clinical study to evaluate the safety and preliminary efficacy of GC511B CAR T cell injection in Adult with DLL3+ r/r SCLC subjects.

Phase:

PHASE1

Details

Lead Sponsor:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborator:

Gracell Biotechnologies (Shanghai) Co., Ltd.